Mebhydrolin diminishes or abolishes the main actions of histamine in the body by blocking of histamine receptors.

Mebhydrolin Napadisylate is indicated in-

• Allergic disease or symptoms such as urticaria
• Pruritus of various origin
• Eczema
• Itching
• Drug rash
• Insect bites
• Allergic conjunctivitis
• Dermatitis of nutritional origin
• Hay fever,
• Vasomotor rhinitis
• Allergic asthma.

Adults and children over 10 years: 2-6 tablets daily

Children-

• 5-10 years: 2-4 tablets daily
• 2-5 years: 1-3 tablets daily
• Up to 2 years: 1-2 tablets daily

Treatment should be given in several single doses daily. Mebhydrolin may be swallowed during or shortly after meals. For children, the tablet may be crushed and mixed with food.

• Hypersensitivity to any of the ingredients of Mebhydrolin tablet or to mebhydrolin
• Prostatic hypertrophy, narrow-angle glaucoma.
• First trimester of pregnancy.

Lassitude, dizziness, hypotension, muscular weakness, nausea, vomiting, diarrhoea or constipation, epigastric pain, headache, blurred vision, tinnitus, depression, nightmares, anorexia, dryness of the mouth, tightness of the chest, tingling, sedation, drowsiness etc. may occur.

The substance may cause drowsiness, if affected, driving or operating machinery & alcoholic drinks should be avoided.

Use in Special Populations

Safety in pregnancy and lactation has not been established.

Pregnancy & Lactation

Safety in pregnancy and lactation has not been established.